Issues

2 to 3 million people in France are affected by kidney disease and they are too often not diagnosed early enough to effectively engage them in efforts to preserve their kidney function or to prepare them in the best conditions for renal replacement therapy or a kidney transplant.

Since 2012 (Care pathway guide – Chronic kidney disease in adults approved by the French Health Authority College in February 2012), all healthcare professionals have been in agreement of the need to become more organized in the detection of kidney disease by taking advantage of the advisory role of biologists, as well as the need to develop interoperable digital solutions that enable continuous monitoring, both upstream and downstream, of patients at different stages of kidney failure.

This interoperable digital solution would also need to be fully in line with the objectives and roadmap of Ma santé 2022, a public health initiative launched by the French government.

Objectives

Based on an economic model of conventional relationships between diagnostic professionals and renal units, with the objective of promoting and sharing with patients a digital application for detecting, preventing and monitoring the therapeutic pathway specific to nephrology, implementation of the SY-Néphro solution must comply with the recommendations of the French Health Authority and the specifications of the French digital health portal.

Functionalities

Offers

The digital therapeutic pathway solutions developed by La Valériane are distributed by SY-Noris (www.sy-noris.fr). SY-Noris was founded in 2018 by La Valériane and the Inovie Biology Group (www.inovie.fr) to provide both healthcare networks and professional subscribers access to a range of interoperable remote monitoring and healthcare data sharing solutions.

SY-Néphro is available to all nephrology networks or renal centers (private or public), by agreement with the biology laboratories within their regional health services, on the basis of an annual software interface license, and with an attractive economic model taking into account social security pricing methods.

Market

SY-Néphro is intended for all those professionals who are involved in the management of kidney disease and would like access to a digital solution to help them monitor care pathways as part of their role within a network, and to enable them to improve the quality of their preventive and curative care.

Since January 2018, throughout the French departments of Hérault, Gard, Lozère, Pyrénées-Orientales and Aude, the medical and nursing teams from the AIDER Santé Association, in agreement with the laboratories from the Inovie Group, have been using SY-Néphro with the 10,000 patients in their care in order to improve detection rates, provide faster and more comprehensive preventive care for kidney disease, and to improve the quality of treatment monitoring at every stage of kidney disease.

If you would like more information about SY-Néphro
Contact us by email at contact@lavaleriane.fr
© Copyright - La Valériane - LVHS CORP 2017 - Admin